Cavosonstat is under clinical development by Laurel Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Cavosonstat’s likelihood of approval (LoA) and phase transition for Chronic Obstructive Pulmonary Disease (COPD) took place on 05 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Cavosonstat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Cavosonstat overview

Cavosonstat (N-91115) is under development for the treatment of asthma and chronic obstructive pulmonary disease. The drug candidate is administered orally. It is developed based on Sphera organoid cell culture technology and acts by targeting S-nitroglutathione reductase (GSNOR). It was under development for cystic fibrosis.

Quick View Cavosonstat LOA Data

Report Segments
  • Innovator
Drug Name
  • Cavosonstat
Administration Pathway
  • Oral
Therapeutic Areas
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.